Capricor Therapeutics, Inc.
CAPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.20 | -0.09 | 2.97 |
| FCF Yield | -8.55% | -21.11% | 1.64% | -26.62% |
| EV / EBITDA | -11.57 | -5.15 | -3.01 | -1.72 |
| Quality | ||||
| ROIC | -28.17% | -83.13% | -106.55% | -55.05% |
| Gross Margin | 93.60% | 95.75% | 72.79% | -0.33% |
| Cash Conversion Ratio | 0.99 | 1.15 | -0.17 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 105.90% | 368.47% | 101.85% | -37.54% |
| Free Cash Flow Growth | -50.25% | -1,875.58% | 108.65% | -69.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.54 | 0.24 | 1.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,925.33 | -1,974.58 | -2,461.20 | -4,936.15 |